메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Lim Chaemin (College of Pharmacy Chung-Ang University) Koo Jain (College of Pharmacy Chung‐Ang University Seoul South Korea) 오경택 (중앙대학교)
저널정보
한국약제학회 Journal of Pharmaceutical Investigation Journal of Pharmaceutical Investigation 제53권 제2호
발행연도
2023.3
수록면
213 - 233 (21page)
DOI
10.1007/s40005-022-00597-5

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background Over the past 30 years, brain tumors have been intensively studied with a variety of therapeutic approaches. However, brain cancer is still one of the most lethal forms of cancer, and the mortality rates have still not significantly improved. Since the late 2010s, transcriptomic analysis of medulloblastoma (MB), the most malignant pediatric brain tumor, has been actively conducted. These efforts have facilitated classification of MB into specific subgroups, enabling more molecularly targeted therapies. However, from a pharmaceutical standpoint, there is one more hurdle to overcome, which is the blood-brain barrier (BBB). Area Covered In this review, we provide information on the characteristics of each subgroup of MB and a list of Food and Drug Administration (FDA)-approved drugs or drugs in clinical trials used for the treatment of this disease. In addition, we introduce lists of methods that can overcome the BBB, a major hurdle for MB treatment, by applying nanotechnology. Finally, we provide a general overview of the state of nanomedicine for brain tumors. Expert Opinion Various types of nanotechnologies have been extensively studied and have shown clear advantages for treatment of brain tumors. However, despite the exploration of these various nanoparticles in preclinical studies, the types of nanoparticles evaluated in clinical trials are very limited, and a number of clinical trial failures have also occurred. Therefore, further insights into relevant regulations as well as rational design of nanoparticles for improved reproducibility are required to bridge the gap between preclinical and clinical studies.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0